Robert Driscoll
Stock Analyst at Wedbush
(4.40)
# 1,238
Out of 4,994 analysts
387
Total ratings
44.5%
Success rate
9.4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robert Driscoll
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CMPX Compass Therapeutics | Downgraded: Hold | $8 → $1 | $1.24 | -19.35% | 5 | Sep 22, 2026 | |
| CGEM Cullinan Therapeutics | Reiterated: Buy | $37 → $42 | $21.67 | +93.82% | 20 | Sep 15, 2026 | |
| CRBP Corbus Pharmaceuticals Holdings | Reiterated: Buy | $30 | $7.88 | +280.95% | 7 | Sep 15, 2026 | |
| CBIO Crescent Biopharma | Reiterated: Buy | $27 | $16.44 | +64.23% | 7 | Sep 14, 2026 | |
| GLUE Monte Rosa Therapeutics | Reiterated: Buy | $27 → $37 | $12.60 | +193.65% | 12 | Sep 9, 2026 | |
| RVMD Revolution Medicines | Reiterated: Buy | $201 → $225 | $192.86 | +16.66% | 26 | Aug 27, 2026 | |
| IDYA IDEAYA Biosciences | Reiterated: Buy | $60 | $39.71 | +51.10% | 27 | Aug 20, 2026 | |
| REPL Replimune Group | Reiterated: Buy | $19 | $13.47 | +41.05% | 22 | Aug 17, 2026 | |
| PYXS Pyxis Oncology | Reiterated: Buy | $6 | $3.36 | +78.84% | 3 | Aug 14, 2026 | |
| TNGX Tango Therapeutics | Reiterated: Buy | $33 → $39 | $25.53 | +52.76% | 12 | Aug 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $25 | $9.15 | +173.37% | 11 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $14 | $1.98 | +607.07% | 15 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $41 → $43 | $26.87 | +60.03% | 25 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $11 → $12 | $8.51 | +41.01% | 27 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $53 | $25.57 | +107.27% | 16 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $36 | $11.73 | +206.91% | 31 | Jul 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 | $4.24 | +135.85% | 15 | Jul 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $11 | $2.94 | +274.15% | 18 | Jun 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $80 | $77.74 | +2.91% | 4 | May 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7 → $6 | $0.7324 | +719.22% | 8 | May 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $29 → $34 | $16.51 | +105.94% | 4 | May 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $7 → $5 | $8.98 | -44.32% | 3 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $45 → $36 | $17.47 | +106.07% | 12 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $6 → $1 | $0.982 | +1.83% | 4 | Dec 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $4 | $3.08 | n/a | 13 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $27 | $7.49 | n/a | 1 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7 → $6 | $1.31 | n/a | 14 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $8 → $1.6 | $0.365 | n/a | 10 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $67 | $152.67 | n/a | 1 | Nov 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7 → $6 | $5.01 | n/a | 8 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 | $13.44 | n/a | 4 | Oct 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $7 → $10 | $0.0001 | n/a | 2 | Mar 19, 2020 |
Compass Therapeutics
Sep 22, 2026
Downgraded: Hold
Price Target: $8 → $1
Current: $1.24
Upside: -19.35%
Cullinan Therapeutics
Sep 15, 2026
Reiterated: Buy
Price Target: $37 → $42
Current: $21.67
Upside: +93.82%
Corbus Pharmaceuticals Holdings
Sep 15, 2026
Reiterated: Buy
Price Target: $30
Current: $7.88
Upside: +280.95%
Crescent Biopharma
Sep 14, 2026
Reiterated: Buy
Price Target: $27
Current: $16.44
Upside: +64.23%
Monte Rosa Therapeutics
Sep 9, 2026
Reiterated: Buy
Price Target: $27 → $37
Current: $12.60
Upside: +193.65%
Revolution Medicines
Aug 27, 2026
Reiterated: Buy
Price Target: $201 → $225
Current: $192.86
Upside: +16.66%
IDEAYA Biosciences
Aug 20, 2026
Reiterated: Buy
Price Target: $60
Current: $39.71
Upside: +51.10%
Replimune Group
Aug 17, 2026
Reiterated: Buy
Price Target: $19
Current: $13.47
Upside: +41.05%
Pyxis Oncology
Aug 14, 2026
Reiterated: Buy
Price Target: $6
Current: $3.36
Upside: +78.84%
Tango Therapeutics
Aug 12, 2026
Reiterated: Buy
Price Target: $33 → $39
Current: $25.53
Upside: +52.76%
Aug 6, 2026
Reiterated: Buy
Price Target: $25
Current: $9.15
Upside: +173.37%
Aug 6, 2026
Reiterated: Buy
Price Target: $14
Current: $1.98
Upside: +607.07%
Aug 6, 2026
Reiterated: Buy
Price Target: $41 → $43
Current: $26.87
Upside: +60.03%
Aug 5, 2026
Reiterated: Hold
Price Target: $11 → $12
Current: $8.51
Upside: +41.01%
Aug 5, 2026
Reiterated: Buy
Price Target: $53
Current: $25.57
Upside: +107.27%
Jul 28, 2026
Reiterated: Buy
Price Target: $36
Current: $11.73
Upside: +206.91%
Jul 20, 2026
Reiterated: Buy
Price Target: $10
Current: $4.24
Upside: +135.85%
Jun 4, 2026
Reiterated: Buy
Price Target: $11
Current: $2.94
Upside: +274.15%
May 18, 2026
Reiterated: Buy
Price Target: $80
Current: $77.74
Upside: +2.91%
May 14, 2026
Reiterated: Buy
Price Target: $7 → $6
Current: $0.7324
Upside: +719.22%
May 14, 2026
Reiterated: Buy
Price Target: $29 → $34
Current: $16.51
Upside: +105.94%
May 12, 2026
Reiterated: Sell
Price Target: $7 → $5
Current: $8.98
Upside: -44.32%
May 8, 2026
Reiterated: Buy
Price Target: $45 → $36
Current: $17.47
Upside: +106.07%
Dec 19, 2025
Downgraded: Hold
Price Target: $6 → $1
Current: $0.982
Upside: +1.83%
Aug 7, 2025
Reiterated: Hold
Price Target: $4
Current: $3.08
Upside: n/a
Jul 14, 2025
Initiated Coverage: Buy
Price Target: $27
Current: $7.49
Upside: n/a
May 8, 2025
Reiterated: Buy
Price Target: $7 → $6
Current: $1.31
Upside: n/a
Mar 20, 2025
Downgraded: Hold
Price Target: $8 → $1.6
Current: $0.365
Upside: n/a
Nov 19, 2021
Reiterated: Buy
Price Target: $67
Current: $152.67
Upside: n/a
Mar 8, 2021
Reiterated: Buy
Price Target: $7 → $6
Current: $5.01
Upside: n/a
Oct 5, 2020
Reiterated: Buy
Price Target: $8
Current: $13.44
Upside: n/a
Mar 19, 2020
Downgraded: Hold
Price Target: $7 → $10
Current: $0.0001
Upside: n/a